FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have accepted the agency’s first submission into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.
Similar Posts
Meamo – 11/03/2025
Unapproved New Drugs/Misbranded/BotoxDrug Trials Snapshots
Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.Vanguard Enterprises, LLC. dba Bedrock MFG Recalls Monarch Premium Kratom Powder Because of Possible Health Risk
October 28, 2025, Vanguard Enterprises, LLC. DBA Bedrock MFG of Boise, Idaho is recalling Monarch Premium Kratom brand Bali Gold, Red Bali, Green Maeng Da, and White Elephant powder because product has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimeLonza Guangzhou Pharmaceutical Ltd. | 10/31/25 | 483
Lonza Guangzhou Pharmaceutical Ltd. | 10/31/25 | 483Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.Quality and Regulatory Predictability: Shaping USP Standards – 12/11/2025
This discussion will show how USP public standards strengthen quality, streamline development, support regulatory compliance, and overall, increase regulatory predictability for drugs.